

# MBS Update

## New MBS Items for multiparametric magnetic resonance imaging (mpMRI) of the prostate

### What are the new services?

From 1 July 2018, Medicare rebates will be available for new items covering mpMRI prostate scans for both the diagnosis of prostate cancer (item 63541) and the active surveillance of patients with a proven diagnosis following biopsy histopathology (item 63543). All items include the use of contrast.

### Patient eligibility requirements:

| Item 63541  | Item 63543  |
|---|---|
| <p>For MBS item 63541 the patient must be suspected of having prostate cancer based on:</p> <ul style="list-style-type: none"> <li>a) a digital rectal examination (DRE) which is suspicious for prostate cancer; or</li> <li>b) a person aged less than 70 years, at least two prostate specific antigen (PSA) tests performed within an interval of 1- 3 months are greater than 3.0 ng/ml, and the free/total PSA ratio is less than 25% or the repeat PSA exceeds 5.5 ng/ml; or</li> <li>c) a person aged less than 70 years, whose risk of developing prostate cancer based on family history is at least double the average risk , at least two PSA tests performed within an interval of 1- 3 months are greater than 2.0 ng/ml, and the free/total PSA ratio is less than 25%; or</li> <li>d) a person aged 70 years or older, at least two PSA tests performed within an interval of 1- 3 months are greater than 5.5ng/ml and the free/total PSA ratio is less than 25%.</li> </ul> <p>Note: Relevant family history is a first degree relative with prostate cancer or suspected of carrying a BRCA 1, BRCA 2 mutation.</p> <p><b>Restrictions:</b><br/>Medicare benefits for MBS item 63541 are only payable once per patient in a twelve month period.</p> | <p>For MBS item 63543 the below clinical criteria must be met:</p> <ul style="list-style-type: none"> <li>a) the patient is under active surveillance following a confirmed diagnosis of prostate cancer by biopsy histopathology; and</li> <li>b) the patient is not planning or undergoing treatment for prostate cancer.</li> </ul> <p><b>Restrictions:</b><br/>Benefits for MBS item 63543 are payable for patients with proven diagnosis of prostate cancer following biopsy histopathology who:</p> <ul style="list-style-type: none"> <li>• have not had a diagnostic mpMRI, and</li> <li>• are placed on active surveillance following confirmed diagnosis; or</li> <li>• 12 months following confirmed diagnosis and then every third year thereafter; or at any time there is a clinical concern, or concern with PSA progression.</li> </ul> <p>Note: MBS item 63543 is not to be used for the purpose of treatment, planning or for monitoring after treatment.</p> |

### Who can request these items?

Specialists in the specialty of urology, radiation oncology or medical oncology. General practitioners are not eligible to request these items.